CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 5,044 enrolled
Drug / intervention
COVID-19 convalescent plasmabiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04545047
NCT04545047N/ACompleted
CompareCT.gov

CSP #2030 - Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19

VA Office of Research and Development·observational·Posted Sep 10, 2020·Updated Apr 4, 2024

In Brief

An observational study evaluating COVID-19 convalescent plasma for Coronavirus Disease 2019 (COVID-19). Completed, enrolled 5,044 participants across 2 sites.

Detailed Summary

The purpose of this study is to assess whether convalescent plasma therapy is associated with reduced 30-day all-cause mortality in a population of Veteran inpatients with non-severe coronavirus disease 2019 (COVID-19).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCoronavirus Disease 2019 (COVID-19)
CountriesUnited States
CollaboratorsMayo Clinic

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedSep 10, 2020
Enrollment StartMay 1, 2020
Primary CompletionOct 1, 2021
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 5.8 years ago

Interventions

COVID-19 convalescent plasmabiological

Convalescent plasma collected from individuals who have recovered from COVID-19